2024-12-18 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Report

**1. Performance Comparison & Overview:**

Intuitive Surgical Inc. is a leading developer and manufacturer of robotic surgical systems.

The cumulative return of ISRG is 300.04%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 120.85%.  The difference is 179.2%, placing it at the 95.2nd percentile of historical relative performance compared to the S&P 500 based on the provided data's range.  This indicates strong historical outperformance.  The provided CAGR (Compound Annual Growth Rate) data shows consistently high growth, although the 2020-2022 period shows a significant slowdown, followed by a resurgence in 2022-2024.  The Alpha consistently shows 0, indicating that the returns are likely primarily driven by market movements (Beta is high, reflecting sensitivity to market fluctuations).


**2. Recent Price Movement:**

* **Closing Price:** $545.16
* **5-Day Moving Average:** $543.01
* **20-Day Moving Average:** $543.145
* **60-Day Moving Average:** $516.6402

The stock price is slightly above its short-term moving averages, suggesting a relatively stable trend, although the 60-day MA indicates a stronger upward movement in the recent past.


**3. Technical Indicators & Expected Return:**

* **RSI:** 52.94  (Neutral; neither overbought nor oversold)
* **PPO:** -0.2996 (Slightly bearish; below zero)
* **Recent Relative Divergence (20-day):** +2.4 (Short-term upward trend)
* **Expected Return (Long-term, 2+ years):** 106.5% (significantly higher than S&P 500)

The current price of $545.16 doesn't suggest any dramatic recent price jumps (no evidence of a rapid surge or drop).  The positive relative divergence and long-term expected return indicate potential for continued growth. However, the negative PPO warrants monitoring.


**4. Recent Earnings Analysis:**

The provided earnings data shows a generally upward trend in both revenue and EPS, although there's some quarter-to-quarter fluctuation:

* **Revenue Growth:** Generally increasing quarter-over-quarter.
* **EPS Trends:** Mostly increasing, with a slight dip in the October 2023 quarter before recovering.  There's a duplicate entry for October 18, 2024 which needs clarification.
* **Notable Beats/Misses:**  Cannot be determined without comparing reported numbers to analyst expectations (information not provided).

**5. Financial Information Analysis:**

* **Revenue and Profitability:**  Revenue shows steady growth, with profit margins consistently high, though exhibiting slight fluctuations.  The high profit margins indicate strong operational efficiency.
* **Capital and Profitability:** Equity is increasing, showing growth in the company's net worth.  ROE (Return on Equity) shows some variability but remains generally positive, indicating effective utilization of shareholder capital.


**6. News and Recent Issues:**

No recent (within the last two days) earnings news is mentioned in the provided text.  Information on recent market outlook, analyst opinions, and performance highlights are missing.


**7. Overall Analysis:**

ISRG demonstrates a strong long-term growth trajectory, significantly outperforming the S&P 500 historically.  While recent technical indicators show a mixed signal (neutral RSI, slightly negative PPO), the company exhibits consistent revenue and earnings growth, high profit margins, and increasing equity. The long-term expected return is substantial.  However, a lack of recent news and analyst opinions limits a complete assessment.  The duplicate entry in the earnings data and absence of information comparing earnings to expectations requires further investigation.

**8. Recommendations:**

Further research is needed to fully assess the current valuation and potential risks.  Investigating analyst ratings and expectations is crucial.  Despite the historical outperformance,  the recent slowdown in 2020-2022 necessitates cautious optimism. The long-term outlook remains positive, especially given the substantial expected return, contingent upon the company's continued success in the robotic surgery market.  The high beta indicates higher risk associated with market volatility.  Considering a long-term investment strategy would likely mitigate this risk.
